Separate Licences May Soon Be Mandatory for Wholesale Bulk Drug Dealers

Centre proposes stricter monitoring of bulk drug sales and supply chains, aiming to strengthen control over medicines covered under the NDPS Act and tackle antimicrobial resistance.

Last Updated : Thursday, 19 November 2026
Follow us :

New Delhi: The Central Government is preparing to take a major step towards ensuring transparency and accountability in the pharmaceutical trade. Wholesale dealers selling bulk drugs, which are the active and inactive ingredients used in medicines, may soon be required to obtain a separate licence.

The Union Ministry of Health and Family Welfare has proposed amendments to the Drugs Rules, 1945, through a draft notification. The move aims to strengthen oversight of the pharmaceutical supply chain and improve accountability in the wholesale drug trade.

Separate Licence Instead of a Common One

Currently, a common licensing system applies to the wholesale sale of drug formulations as well as bulk drugs. Under the proposed amendments, the government plans to introduce a separate application form, Form 19-BC, and a licence form, Form 20-BC, for businesses dealing in bulk drugs.

This will allow authorities to separately monitor wholesale dealers, their business activities and the categories of drugs they handle.

Narcotic and Psychotropic Drugs Also Under Watch

Under the proposed system, dealers will have to specify the categories of bulk drugs they intend to trade in while applying for a licence. This will also include medicines covered under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985.

Furthermore, the sale of bulk drugs will have to take place under the personal supervision of a competent person. This provision is expected to help establish accountability in the storage, distribution and sale of medicines.

Stronger Measures to Tackle Antimicrobial Resistance

The government believes that a separate licensing system will help address the challenge of antimicrobial resistance (AMR) and strengthen monitoring of the movement of medicines covered under the NDPS Act.

The proposal has also received approval from the Drugs Consultative Committee during its 67th meeting and the Drugs Technical Advisory Board at its 93rd meeting.

Existing Licence Holders to Get Time

Existing licence holders will be given sufficient time to transition to the new system.

The revised provisions will become applicable to them after the expiry of the retention period of their current licence or 12 months after the final publication of the amendment, whichever is later.

Suggestions and Objections Invited Within 30 Days

The Ministry has issued the draft notification under GSR No. 987(E), dated November 2, 2026.

Members of the public and other stakeholders can submit their suggestions and objections within 30 days from the date the notification is made available to the public.

Submissions can also be sent via email to drugsdiv-mohfw@gov.in.

Tags :